Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Protein S deficiency and novel oral anticoagulants: an intriguing case.
Tàssies D, García de Frutos P.
Thromb Res. 2014 Jul;134(1):1-2. doi: 10.1016/j.thromres.2014.03.008. Epub 2014 Mar 6. No abstract available.
Similar articles
PROS1 mutations associated with protein S deficiency in Polish patients with residual vein obstruction on rivaroxaban therapy.
Wypasek E, Potaczek DP, Alhenc-Gelas M, Undas A.
Thromb Res. 2014 Jul;134(1):199-201. doi: 10.1016/j.thromres.2014.01.023. Epub 2014 Jan 23. No abstract available.
First case of protein S deficiency due to a translocation t(3;21)(q11.2;q22).
Hurtado B, Nadal M, Margarit E, Sánchez A, Abasolo N, García N, Doménech P, Sala N.
Thromb Haemost. 2009 May;101(5):977-9. No abstract available.
Oral rivaroxaban for symptomatic venous thromboembolism.
Landman GW, Gans RO.
N Engl J Med. 2011 Mar 24;364(12):1178; author reply 1178. doi: 10.1056/NEJMc1100734#SA1. No abstract available.
Review of an article: oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN Investigators et al. N Engl J Med 2010; 363(26):2499-2510.
Nunnelee JD.
J Vasc Nurs. 2011 Jun;29(2):89. doi: 10.1016/j.jvn.2011.03.002. No abstract available.
New oral anticoagulants.
Sun D, Lazo-Langner A.
CMAJ. 2013 Mar 5;185(4):E212. doi: 10.1503/cmaj.120078. Epub 2012 Nov 12. No abstract available.
Normal prothrombin time in the presence of therapeutic levels of rivaroxaban.
van Veen JJ, Smith J, Kitchen S, Makris M.
Br J Haematol. 2013 Mar;160(6):859-61. doi: 10.1111/bjh.12173. Epub 2012 Dec 29. No abstract available.
More effective, simpler-to-use clot-buster is on the way. Clot-prevention drug could save lives after joint replacement.
[No authors listed]
Duke Med Health News. 2008 Oct;14(10):6. No abstract available.
Compound heterozygous mutations in the PROS1 gene responsible for quantitative and qualitative protein S deficiency.
Yamanouchi J, Hato T, Tamura T, Fujiwara H, Yakushijin Y, Yasukawa M.
Int J Hematol. 2009 Nov;90(4):537-539. doi: 10.1007/s12185-009-0430-2. Epub 2009 Oct 14. No abstract available.
Rivaroxaban for the treatment of pulmonary embolism.
Vanassche T, Verhamme P.
Adv Ther. 2013 Jun;30(6):589-606. doi: 10.1007/s12325-013-0041-4. Epub 2013 Jun 27. Review.
Inherited protein S deficiency as a result of a large duplication mutation of the PROS1 gene detected by multiplex ligation-dependent probe amplification.
Choung HS, Kim HJ, Gwak GY, Kim SH, Kim DK.
J Thromb Haemost. 2008 Aug;6(8):1430-2. doi: 10.1111/j.1538-7836.2008.03026.x. Epub 2008 May 17. No abstract available.
More on normal prothrombin times in the presence of therapeutic levels of rivaroxaban--early experience from King's College Hospital.
Patel JP, Roberts LN, Chitongo PB, Patel RK, Arya R.
Br J Haematol. 2013 Sep;162(5):717-8. doi: 10.1111/bjh.12423. Epub 2013 Jun 15. No abstract available.
Heerlen polymorphism associated with type III protein S deficiency and factor V Leiden mutation in a Polish patient with deep vein thrombosis.
Blood Coagul Fibrinolysis. 2014 Jan;25(1):84-5. doi: 10.1097/MBC.0b013e328365032c.
[Application of rivaroxabane in patients with proteins C and S deficiency].
Poliantsev AA, Frolov DV, Linchenko DV, Shchelokova IuV.
Khirurgiia (Mosk). 2014;(9):68-71. Russian. No abstract available.
Venous gangrene and intravascular coagulation and fibrinolysis in a patient treated with rivaroxaban.
Rosenbaum AN, Yu RC, Rooke TW, Heit JA.
Am J Med. 2014 Jun;127(6):e7-8. doi: 10.1016/j.amjmed.2014.02.014. Epub 2014 Feb 22. No abstract available.
[Therapy of pulmonary embolism. Rivaroxaban is superior to standard therapy].
Einecke D.
MMW Fortschr Med. 2012 Apr 19;154(7):24. German. No abstract available.
Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S--a decision analysis.
van den Belt AG, Hutten BA, Prins MH, Bossuy PM.
Thromb Haemost. 2000 Nov;84(5):758-63.
A novel nonsense mutation Tyr301* of PROS1 causing protein S deficiency.
Jang MA, Kim SH, Kim DK, Kim HJ.
Blood Coagul Fibrinolysis. 2015 Mar;26(2):223-4. doi: 10.1097/MBC.0000000000000217.
[Oral Rivaroxaban (Xarelto)].
Peeters S, Warnez M.
J Pharm Belg. 2013 Mar;(1):37-40. Review. French. No abstract available.
Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.
Sattari M, Lowenthal DT.
Am J Ther. 2011 Jul;18(4):332-8. doi: 10.1097/MJT.0b013e3181da0773. Review.
Filters: Manage Filters